UBS Group Issues Positive Forecast for Kodiak Sciences (NASDAQ:KOD) Stock Price

Kodiak Sciences (NASDAQ:KOD) had its target price hoisted by UBS Group from $120.00 to $150.00 in a research note released on Friday morning,Benzinga reports. The firm currently has a buy rating on the stock.

KOD has been the subject of a number of other research reports. The Goldman Sachs Group initiated coverage on Kodiak Sciences in a report on Wednesday, September 30th. They issued a “neutral” rating and a $103.00 target price for the company. JPMorgan Chase & Co. boosted their price target on Kodiak Sciences from $56.00 to $66.00 and gave the stock an “overweight” rating in a research note on Monday, August 3rd. Jefferies Financial Group reaffirmed a “buy” rating and set a $112.00 price target on shares of Kodiak Sciences in a report on Monday, September 28th. Wall Street Zen raised Kodiak Sciences from a “strong sell” rating to a “sell” rating in a research report on Sunday, October 4th. Finally, Lifesci Capital increased their price objective on Kodiak Sciences from $85.00 to $145.00 and gave the company an “outperform” rating in a research report on Monday, September 28th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $109.00.

Kodiak Sciences Stock Performance

Shares of KOD traded up $2.94 on Friday, hitting $111.19. 970,804 shares of the stock traded hands, compared to its average volume of 864,388. The company has a market capitalization of $6.99 billion, a PE ratio of -27.25 and a beta of 2.02. The business has a 50 day simple moving average of $76.72 and a 200 day simple moving average of $45.75. Kodiak Sciences has a one year low of $18.15 and a one year high of $112.79.

Kodiak Sciences (NASDAQ:KOD) last released its quarterly earnings data on Thursday, November 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $0.01. On average, equities analysts expect that Kodiak Sciences will post -3.97 earnings per share for the current year.

Insider Activity at Kodiak Sciences

In related news, Director Bros. Advisors Lp Baker acquired 86,432 shares of the firm’s stock in a transaction dated Thursday, November 5th. The stock was purchased at an average cost of $98.51 per share, with a total value of $8,514,416.32. Following the completion of the acquisition, the director directly owned 20,424,859 shares of the company’s stock, valued at approximately $2,012,052,860.09. This trade represents a 0.42% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have purchased 2,188,845 shares of company stock valued at $181,326,862 in the last three months. Insiders own 44.40% of the company’s stock.

Institutional Investors Weigh In On Kodiak Sciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. KBC Group NV purchased a new stake in Kodiak Sciences during the 1st quarter valued at $39,000. EverSource Wealth Advisors LLC lifted its holdings in shares of Kodiak Sciences by 94.5% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,927 shares of the company’s stock valued at $73,000 after buying an additional 936 shares during the period. Sterling Capital Management LLC lifted its holdings in shares of Kodiak Sciences by 850.0% during the 3rd quarter. Sterling Capital Management LLC now owns 1,311 shares of the company’s stock valued at $124,000 after buying an additional 1,173 shares during the period. E Fund Management Co. Ltd. bought a new position in shares of Kodiak Sciences during the 2nd quarter valued at $228,000. Finally, Cetera Investment Advisers bought a new position in shares of Kodiak Sciences during the 1st quarter valued at $228,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Kodiak Sciences Company Profile

Kodiak Sciences is a clinical-stage biopharmaceutical company focused on developing treatments for retinal and other eye diseases. The company’s research centers on therapies designed to address conditions involving damage to the retina and vision loss. Kodiak’s technology platform combines therapeutic antibodies with a biopolymer to create antibody biopolymer conjugates, which are designed to provide sustained treatment effects. Its development programs have included KSI-301, an investigational therapy targeting vascular endothelial growth factor (VEGF) for retinal diseases.